he Opioid Crisis Response Act of 2018 is the result of seven bipartisan Senate hearings on the opioid crisis and public feedback
Legislation also reflects input and insight Senator Murray heard from people in Washington state as she met with families, community leaders and members of law enforcement affected by this opioid crisis
(Washington, D.C.) – Today, Senator Patty Murray (D-WA), top Democrat on the Senate health committee, joined the committee’s top Republican, Senator Lamar Alexander (R-TN) to introduce bipartisan legislation to address the urgent opioid crisis and said the committee will consider the legislation on Tuesday, April 24th.
The Opioid Crisis Response Act of 2018 (S. 2680) will improve the ability of the Departments of Education, Labor, and Health and Human Services (HHS), including the Food and Drug Administration (FDA), the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), the Health Resources and Service Administration (HRSA), and the Substance Abuse and Mental Health Services Administration (SAMHSA) to address the crisis, including the ripple effects of the crisis on children, families, and communities, and improve data sharing between states.
The legislation which is composed of 40 different proposals, mostly from Democratic and Republican members of the Senate health committee, is the result of seven bipartisan hearings over several months, and feedback from the public.
“No matter where I go in Washington state, I hear from families about how devastating the opioid crisis has been to their lives and to their community. I’m grateful to members on both sides of the aisle for their strong work on the policies in our bill, which will offer families and communities in Washington and across the country much-needed tools and resources as they continue working to stop this epidemic and rebuild. The work isn’t over, and I look forward to more bipartisan progress in support of everyone on the frontlines of the opioid crisis looking to Congress for support,” said Senator Murray.
The Senate health committee has held a series of hearings this Congress to hear input on ways the federal government can be a better partner for states and communities on the front lines of the opioid crisis.
On October 5, 2017, the Senate health committee held the first hearing of the series which focused on the federal response to the opioid crisis, and on November 30, 2017, the committee heard from witnesses representing states, communities, and providers on what they are doing and what, if any, new authorities they need from the federal government to fight the crisis. On January 9, the committee heard from author Sam Quinones, who has extensively researched and written about the opioid crisis. On February 8, the committee held a hearing focused on listening to the needs of children and families affected by the opioid crisis. On February 27, the committee held a hearing on the role technology and data play in responding to the crisis. On March 8, the committee heard from some of the nation’s governors about how they are coming up with innovative solutions and leading the fight against the unique problems their states face in the midst of the opioid crisis. On April 10, the committee held a hearing to examine the discussion draft of the Opioids Crisis Response Act.
Over the past several years, Senator Murray has visited communities throughout Washington state, meeting with patients, families, community leaders and medical professionals fromEverett to Seattle to Longview as well as others impacted by the opioid crisis, and brought the stories people shared to Washington D.C. as she worked for policies that helped address their needs.
The Opioid Crisis Response Act of 2018 will:
· Reauthorize and improve grants to states and Indian Tribes for prevention, response, and treatment of the opioid crisis, authorized in 21st Century Cures, for three more years.
· Spur development and research on of non-addictive painkillers, and other strategies to prevent, treat, and manage pain and substance use disorders through additional flexibility for the NIH.
· Clarify FDA’s regulatory pathways for medical product manufacturers through guidance for new non-addictive pain and addiction products.
· Encourage responsible prescribing behavior by clarifying FDA authority to require packaging and disposal options for certain drugs, such as opioids to allow a set treatment duration—for example “blister packs,” for patients who may only need a 3 or 7 day supply of opioids—and give patients safe disposal options.
· Improve detection and seizure of illegal drugs, such as fentanyl, through stronger FDA and Customer Border Protection coordination.
· Clarify FDA’s post-market authorities for drugs, such as opioids, which may have reduced efficacy over time, by modifying the definition of an adverse drug experience to include such situations.
· Provide support for states to improve their Prescription Drug Monitoring Programs (PDMPs) and encourage data sharing between states so doctors and pharmacies can know if patients have a history of substance misuse.
· Strengthen the health care workforce to increase access to mental health services in schools and community-based settings and to substance use disorder services in underserved areas.
· Authorize CDC’s work to combat the opioid crisis, including providing grants for states, localities, and tribes to collect data and implement key prevention strategies.
· Address the effects of the opioids crisis on infants, children, and families, including by helping states improve plans of safe care for infants born with neonatal abstinence syndrome and helping to address child and youth trauma.
· Authorize the Department of Labor to address the economic and workforce impacts for communities affected by the opioid crisis, through grants targeted at workforce shortages for the substance use and mental health treatment workforce, and to align job training and treatment services.
· Improves treatment access to patients by requiring the Drug Enforcement Administration to issue regulations on how qualified providers can prescribe controlled substances in limited circumstances via telemedicine.
· Allow hospice programs to safely and properly dispose of unneeded controlled substances to help reduce the risk of diversion and misuse.